Shanghai Zerun Biotechnology Co.,Ltd. researches, develops, and commercializes human vaccines. The company develops vaccines based on its platform technologies, including recombinant protein/antigen expression systems in yeast, insect cells, and E. coli; recombinant “virus-like particle" antigen production and characterization technology; novel adjuvant development, production, and assessment platform technology; and inactivated virus based vaccine development technologies. It offers human papillomavirus, hepatitis A inactivated, and other recombinant vaccines. The company was founded in 2003 and is based in Shanghai, China. Shanghai Zerun Biotechnology Co.,Ltd. operates as a subsidiary of Walvax Biotechnology Co.,Ltd.